Guerbet announces that it has signed an exclusive agreement with icometrix for the distribution in France, Italy and Brazil of icobrain, their Saas (Software as a Service) artificial intelligence (AI)-based medical imaging solution.
Icobrain is designed to help radiologists and neurologists diagnose and monitor patients with neurological disorders. The AI software extracts clinically meaningful information from brain CT or MRIs scans of patients with multiple sclerosis, dementia or brain injury. Icobrain can therefore be used to automate the currently manual process of identifying, marking and quantifying volumes of brain structures identified.
Icobrain has obtained marketing authorisations in numerous countries, including the United States, Europe, Canada, Brazil, Australia, Japan and India and is already used in more than 100 hospitals and imaging centres across the world, as well as in clinical studies from major global pharmaceutical companies.
“This agreement will allow more patients with neurological disorders to benefit from the icobrain AI technology. It will also allow Guerbet to expand its portfolio of augmented intelligence solutions beyond oncology, with the same aim of helping radiologists diagnose better and faster than ever before,” said François Nicolas, chief digital officer for Guerbet.
“There is a strong medical need to help radiologists, neurologists and patients with neurological disorders. This collaboration with Guerbet will allow us to serve hospitals in France, Italy and Brazil with the best support”, says Wim Van Hecke, CEO of icometrix. “Guerbet has many years of expertise in the radiology market and has a great reputation. We are very much looking forward to this strategic partnership”.